Clinical Trial

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Study acronym: SEMAFOLLOW
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-13; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT07423481
Lead Sponsor Nantes University Hospital
Collaborators: Novo Nordisk A/S
Conditions Obesity & Overweight
Enrollment 3,000 participants
Start Date 2026-06-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-13